Strides Pharma Science Limited announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered a strategic product development partnership with Monmouth Junction-based Kenox Pharmaceuticals Inc., a fast-growing contract development and manufacturing company specializing in orally inhaled and nasal drug products (OINDPs).
Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the U.S. market across diverse therapeutic indications. Specific product details remain confidential at this stage.
“Our strategic partnership with Strides is a significant milestone for Kenox,” said Dr. Sitaram Velaga, founder, president and CEO of Kenox Pharmaceuticals Inc. “This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price. Furthermore, this milestone accelerates Kenox’s growth plans.”
The partnership will advance a pipeline of nasal spray products for the U.S. market, combining Strides’ commercial strengths with Kenox’s OINDP expertise to deliver affordable, high-quality therapies to patients.
“We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space,” said Aditya Kumar, executive director, Business Development, Strides Pharma Science Limited. “Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our U.S. facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain.
“Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths, allowing us to accelerate our range of nasal spray offerings in the U.S. market.”
